Novartis AG Cash Flow from Operating Activities 2012-2026 | NVS
Novartis AG annual/quarterly cash flow from operating activities history and growth rate from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Novartis AG cash flow from operating activities for the quarter ending March 31, 2026 was $3.676B, a 0.85% increase year-over-year.
- Novartis AG cash flow from operating activities for the twelve months ending March 31, 2026 was $50.009B, a 19.55% increase year-over-year.
- Novartis AG annual cash flow from operating activities for 2025 was $19.144B, a 8.66% increase from 2024.
- Novartis AG annual cash flow from operating activities for 2024 was $17.619B, a 21.86% increase from 2023.
- Novartis AG annual cash flow from operating activities for 2023 was $14.458B, a 1.56% increase from 2022.
|
Novartis AG Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $19,144 |
| 2024 | $17,619 |
| 2023 | $14,458 |
| 2022 | $14,236 |
| 2021 | $15,071 |
| 2020 | $13,650 |
| 2019 | $13,625 |
| 2018 | $14,272 |
| 2017 | $12,621 |
| 2016 | $11,475 |
| 2015 | $11,897 |
| 2014 | $13,897 |
| 2013 | $13,174 |
| 2012 | $14,194 |
| 2011 | $14,309 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $293.951B | $54.532B |
| Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |